DENVER – (BUSINESS WIRE) – October 14, 2021–
Ripple, a leading brand of cannabis edibles, advances scientific understanding of how âreal worldâ cannabis products work. The results of a recent independent human clinical study of THC edibles are helping to increase the transparency of the cannabis industry for the benefit of consumers.
This press release features multimedia. See the full version here: https://www.businesswire.com/news/home/202111014005360/en/
(Graphic: Business Wire)
The study, independently conducted by researchers at Colorado State University and published in the open access peer-reviewed scientific journal Medications, explored the pharmacokinetics of edible THC. He also found that all Ripple products were absorbed into the bloodstream. much faster than market-leading gummy products, including those marketed as âfastâ. The differences were seen across the board, from Ripple Gummies (2.3 times faster than the main gummy), Ripple Dissolvables (1.9 times faster) and Ripple QuickSticks (1.5 times faster).
While other THC edible brands claim on their labels that they work or absorb quickly, no company has so far substantiated such a claim using the products actually available for sale. This study represents the first human clinical justification for a âfast-actingâ claim in edible cannabis products, and validates Ripple’s commitment to backing all of its products and claims with rigorous science.
âOur commitment to rationale and honesty makes us an outlier in an industry full of hyperbole and outright lies,â said Justin Singer, CEO and co-founder of Ripple. âCompanies like to use terms like ‘water soluble’ or ‘nano,’ but these are just meaningless buzzwords without real scientific evidence. We believe in the truth in advertising even when no one is applying it, so we have invested in research to prove, both to consumers and to ourselves, that our products do what we say they do.
Importantly, the results represent the first published human clinical research study of commercially available THC products. âThe FDA continues to call for ‘real world evidence’ on consumer cannabinoid products. Well, there is no more of a real world than real consumer products tested with real consumers, âSinger said. âUnfortunately, because the products in this study came from dispensaries rather than the DEA / NIDA, the FDA is likely to ignore these results because they have all the other research based on legal cannabis products. Too bad, but we hope nonetheless that this study will inform smart policy making as cannabinoids continue to grow in popularity and availability. Consumers are not waiting for federal regulators, and neither are the scientific community, âSinger said. .
The study, led by Dr Christopher Bell, director of CSU Integrative biology laboratory, used a randomized, placebo-controlled trial crossover design to compare the absorption patterns of a 10 mg dose of THC, given to seven healthy adults over six weeks, in six different formats: Ripple Gummies, Ripple QuickDissolves, Ripple QuickSticks, a leading âsourâ gum on the market, a âgummy, and a placebo candy without THC. Blood THC concentrations were measured at several points over four hours after ingestion and analyzed using an ultra high pressure liquid chromatography (HPLC) test. Each subject served as its own control, removing the possibility of variability between people and providing high statistical significance to the results.
âIt was essential for us to obtain and rely on observable quantitative data – blood levels of THC – rather than subjective self-reports, such as ‘I’m starting to feel good now,'” said Keith Woelfel. , R&D director of Ripple. “This pharmacokinetics data lays the foundation for understanding how our products work in the body. And it answers fundamental questions that matter deeply to consumers. Questions such as “how fast is this going to hit me?” And ‘How long is this going to last?’
âCannabis consumers have the right to demand high quality products that actually do what they say on their labels,â Singer added. “At Ripple, we will continue to invest heavily in credible research to ensure that they can always use our products with confidence and enjoyment.”
Ripple manufactures the most innovative and consistent products in the marijuana market, including: Ripple Dissolvables, the fast acting water soluble OG powder; Gelled waves, clinically proven to be 2X faster than the competition; and Ripple QuickSticks, the most convenient and fun way to get THC the fastest.
At Ripple, our mission is to improve people’s lives through cannabinoids. We give people consistent experiences they can count on, and we deliver those experiences twice as fast as the competition. We pride ourselves on great products, great people, and great science. We are particularly focused on quality, which for us means doing things the right way, right from the start.
Learn more about Try Ripple.com
View source version on businesswire.com:https://www.businesswire.com/news/home/202111014005360/en/
CONTACT: Madison Ware
Grasslands: an agency focused on journalism
KEYWORD: UNITED STATES NORTH AMERICA COLORADO
INDUSTRY KEYWORD: FOOD / DRINK ALTERNATIVE MEDICINE HEALTH DETAIL TOBACCO
Copyright Business Wire 2021.
PUB: 10/14/2021 10:03 am / DISC: 10/14/2021 10:03 am